PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus by Bowes, John et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Bowes, J., Loehr, S, Badu-Aggrey, A, Uebe, S, Bruce, IN, Feletar, M.,
Marzo-Ortega, H., Helliwell, P, Ryan, AW, Kane, D, Korendowych, E, Ale-
nius, GM, Giardina, E, Packham, J, McManus, R., Fitzgerald, O., Brown,
Matthew A., Behrens, F, Burkhardt, H, McHugh, N, Hüffmeier, U., Ho, P,
Reis, A, & Barton, A.
(2015)
PTPN22 is associated with susceptibility to psoriatic arthritis but not psori-
asis: evidence for a further PsA-specific risk locus.
Annals of the Rheumatic Diseases, 74(10).
This file was downloaded from: https://eprints.qut.edu.au/110800/
c© 2015 BMJ Journals
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
https://doi.org/10.1136/annrheumdis-2014-207187
CONCISE REPORT
PTPN22 is associated with susceptibility to psoriatic
arthritis but not psoriasis: evidence for a further
PsA-speciﬁc risk locus
John Bowes,1 Sabine Loehr,2 Ashley Budu-Aggrey,1,3 Steffen Uebe,2 Ian N Bruce,1,3,4
Marie Feletar,5 Helena Marzo-Ortega,6 Philip Helliwell,6 Anthony W Ryan,7
David Kane,8 Eleanor Korendowych,9 Gerd-Marie Alenius,10 Emiliano Giardina,11
Jonathan Packham,12 Ross McManus,7 Oliver FitzGerald,13 Matthew A Brown,14
Frank Behrens,15 Harald Burkhardt,15 Neil McHugh,9 Ulrike Huffmeier,2 Pauline Ho,1,4
Andre Reis,2 Anne Barton1,3,4
Handling editor Tore K Kvien
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2014-207187).
For numbered afﬁliations see
end of article.
Correpondence to
Professor Anne Barton,
Arthritis Research UK Centre
for Genetics and Genomics,
The University of Manchester,
Manchester M13 9PT, UK;
anne.barton@manchester.ac.uk
Received 19 December 2014
Revised 3 March 2015
Accepted 5 April 2015
Published Online First
28 April 2015
▸ http://dx.doi.org/10.1136/
annrheumdis-2014-207190
To cite: Bowes J, Loehr S,
Budu-Aggrey A, et al. Ann
Rheum Dis 2015;74:
1882–1885.
ABSTRACT
Objectives Psoriatic arthritis (PsA) is a chronic
inﬂammatory arthritis associated with psoriasis; it has a
higher estimated genetic component than psoriasis
alone, however most genetic susceptibility loci identiﬁed
for PsA to date are also shared with psoriasis. Here we
attempt to validate novel single nucleotide
polymorphisms selected from our recent PsA
Immunochip study and determine speciﬁcity to PsA.
Methods A total of 15 single nucleotide
polymorphisms were selected (PImmunochip <1×10
−4) for
validation genotyping in 1177 cases and 2155 controls
using TaqMan. Meta-analysis of Immunochip and
validation data sets consisted of 3139 PsA cases and
11 078 controls. Novel PsA susceptibility loci were
compared with data from two large psoriasis studies
(WTCCC2 and Immunochip) to determine PsA speciﬁcity.
Results We found genome-wide signiﬁcant association
to rs2476601, mapping to PTPN22 ( p=1.49×10−9,
OR=1.32), but no evidence for association in the
psoriasis cohort (p=0.34) and the effect estimates were
signiﬁcantly different between PsA and psoriasis
(p=3.2×10−4). Additionally, we found genome-wide
signiﬁcant association to the previously reported
psoriasis risk loci; NOS2 (rs4795067, p=5.27×10−9).
Conclusions For the ﬁrst time, we report genome-wide
signiﬁcant association of PTPN22 (rs2476601) to PsA
susceptibility, but no evidence for association to psoriasis.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inﬂammatory
arthritis associated with psoriasis; in UK popula-
tions the prevalence rate of PsA in patients with
psoriasis is estimated to be 14%.1 While psoriasis
has a serious impact on the patient’s quality of life,
those suffering from PsA have been found to have a
lower quality of life than psoriasis alone.2
PsA is a complex disease with environmental and
genetic risk factors contributing to the overall liabil-
ity. The genetic factors contributing to the suscepti-
bility of PsA are not fully understood, but PsA is
estimated to have a larger genetic component than
psoriasis.3 This suggests a substantial difference in
the genetic architecture of the two diseases with a
heavier genetic burden for PsA. Many of the genetic
risk loci reported as associated with PsA susceptibility
are shared with psoriasis indicating the importance of
pleiotropic effects within shared molecular pathways
mediated by the presence of cutaneous psoriasis in
both phenotypes. Recent studies have identiﬁed
PsA-speciﬁc loci that begin to explain this increased
burden; the presence of glutamic acid at the amino
acid position 45 in HLA-B has been shown to be a
risk factor for PsA in a psoriasis cohort and our
recent Immunochip study conﬁrmed the independent
HLA-B association.4 In addition, we reported evi-
dence for a PsA-speciﬁc risk locus at chromosome
5q31 and distinct PsAvariants at the IL23R locus.5
The aim of the current study was to test the loci
at suggestive levels of signiﬁcance in our recent
Immunochip analysis to identify novel PsA loci in a
large collection of PsA cases and controls collected
from the UK, Ireland, Germany, Australia, Sweden
and Italy.
METHODS
Samples
All samples included in this study were of
European ancestry and provided written informed
consent. Summary statistics and genotype data were
available from the PsA Immunochip study compris-
ing 1962 cases and 8923 controls.5 In addition
genotype data was available for the psoriasis
Wellcome Trust Case Control Consortium 2
(WTCCC2) study which contained 1784 psoriasis
samples following exclusion of known PsA samples
and 5175 controls.6 A total of 1352 PsA case and
2164 control DNA samples, independent of those
tested as part of the Immunochip study, were avail-
able for genotyping collected from Germany
(cases=508, controls=920), Sweden (cases=417,
controls=1079) and Italy (cases=427, con-
trols=165). A description of clinical characteristics
for the three cohorts is provided in online supple-
mentary table S1. Data for a total of 3139 PsA
cases and 11 078 controls were available for this
study following quality control.
SNP selection and genotyping
A total 15 single nucleotide polymorphisms (SNPs)
were selected from the Immunochip study based on
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a signiﬁcance threshold of p<1×10−4.7 Genotyping was per-
formed using the Life Technologies TaqMan chemistry on the
QuantStudio genotyping platform at the University of Erlangen,
Germany. Sample and SNPs with low call rates (<0.9) were
excluded prior to analysis. All genotype cluster plots were
manually reviewed and SNPs were screened for deviation from
Hardy-Weinberg equilibrium in control samples (Bonferroni cor-
rected p<3.3×10−3).
Statistical analysis
Association testing was performed using logistic regression
implemented in PLINK and meta-analysis of Immunochip and
validation summary statistics was performed, weighting SNPs by
inverse-variance and assuming ﬁxed effects, using the software
package METAL.
For loci not previously reported as being associated with psor-
iasis susceptibility we investigated PsA-speciﬁcity using two large
psoriasis studies. First, we tested association to psoriasis using
genotype data from WTCCC2 and association summary statis-
tics from the largest psoriasis study to date, consisting of 10 588
psoriasis cases and 22 806 controls,8 from ImmunoBase (http://
www.immunobase.org). Second, we compared effect estimates
in PsA to psoriasis using multinomial logistic regression using
genotype data for PsA cases and controls from Immunochip and
psoriasis genotype data from WTCCC2 performed in Stata.
Finally, we directly compared PsA and psoriasis genotypes, with
PsA coded as cases and psoriasis coded as controls. Sex differen-
tiated associations were investigated by analysing men and
women separately and comparing differences in effect estimates
using Cochrane’s Q statistic using Immunochip genotype data.
To control for phenotype misclassiﬁcation with rheumatoid
arthritis (RA), we included a genetic risk score (GRS) comprised
of the 41 non-HLA RA susceptibility SNPs reported in the RA
Immunochip study, weighted by odds ratio (OR), as a covariate
and recalculated the PsA Immunochip summary statistics.9 10
RESULTS
Following quality control of the validation genotype data a total
of 13 SNPs for 1177 cases and 2155 controls was available
for analysis. Meta-analysis of the validation samples with
Table 1 Summary statistics for Immunochip, validation and meta-analysis of selected SNPs
rs chr bp Gene Risk/non-risk
Immunochip
(cases=1962,
controls=8923)
Validation
(cases=1177,
controls=2155)
Meta-analysis (cases=3139,
controls=11 078)
RAF p Value OR p Value OR p Value OR I2 Q
rs2476601 1 114 377 568 PTPN22 A/G 0.10 1.29E-05 1.28 1.28E-05 1.44 1.49E-09 1.32 0 0.65
rs4795067 17 26 106 675 NOS2 G/A 0.34 1.94E-07 1.21 7.42E-03 1.25 5.27E-09 1.22 0 0.75
rs984971 2 163 224 521 KCNH7 G/A 0.36 3.62E-06 0.84 0.02 0.87 2.29E-07 0.85 0 0.61
rs1306395 2 61 076 272 LINC01185 C/T 0.43 2.99E-05 0.86 0.04 0.88 3.43E-06 0.87 0 0.85
rs7552167 1 24 518 643 IFNLR1 A/G 0.14 1.53E-05 0.79 0.10 0.88 7.36E-06 0.82 35.6 0.20
rs8106664 19 10 728 030 SLC44A2 G/T 0.23 3.28E-06 0.81 0.13 0.89 1.67E-06 0.83 0 0.52
rs2392581 7 38 573 234 AMPH G/A 0.42 6.90E-05 0.87 0.17 0.93 4.42E-05 0.88 51.7 0.10
rs8103241 19 13 122 612 NFIX G/A 0.46 9.08E-05 0.87 0.19 0.92 5.41E-05 0.88 0 0.52
rs1133071 9 32 455 674 DDX58 C/T 0.30 3.36E-05 1.17 0.20 1.09 2.49E-05 1.15 64.9 0.06
rs6713082 2 62 516 544 B3GNT2 A/C 0.24 4.59E-05 1.18 0.46 1.05 9.44E-05 1.15 71.7 0.03
rs2298428 22 21 982 892 YDJC T/C 0.18 4.38E-05 1.20 0.56 1.04 2.35E-04 1.14 66.8 0.03
rs8016947 14 35 832 666 NFKBIA T/G 0.44 9.65E-05 0.87 0.73 1.02 1.49E-03 0.91 70.1 0.04
rs7895120 10 129 064 193 DOCK1 T/C 0.14 5.29E-05 0.80 0.87 1.01 1.44E-03 0.87 62.9 0.04
bp, base position; chr, chromosome; I2, heterogeneity index for ORs; Q, Cochrane’s Q statistic for heterogeneity of ORs; RAF, risk allele frequency;
Figure 1 Regional association plots
for the PTPN22 locus for PsA
Immunochip data and meta-analysis of
rs2476601. The x-axis represents
chromosomal position and gene
location. The ﬁrst y-axis represents –
log10 of the observed p value from
logistic regression, secondary y-axis
represents estimated recombination
rates (cM/Mb). Circles represent
genotyped single nucleotide
polymorphisms (SNPs), colour of the
circle represents linkage disequilibrium
(r2) with the index SNP (purple circle).
kb, kilobase; cM, centimorgan; Mb,
megabase.
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Immunochip data resulted in a combined data set of 3139 PsA
cases and 11 078 controls. We identiﬁed genome-wide signiﬁ-
cance to two loci; NOS2 (rs4795067, p=5.27×10−9) and
PTPN22 (rs2476601, p=1.49×10−9) (table 1). Association to
NOS2 has previously been reported to psoriasis; however no
such association has been made to PTPN22 (ﬁgures 1 and 2).
Interestingly we observe a higher effect estimate for rs2476601
in men compared with women (1.31 vs 1.22, respectively) as
previously reported for this SNP in PsA, however this difference
is not statistically signiﬁcant (Q=0.52). We also observe a much
lower minor allele frequency for rs2476601 in the Italian popu-
lation which is consistent with previous studies demonstrating a
North-East to South-West gradient for minor allele frequency
(MAF) across continental Europe.11
As SNPs at the PTPN22 locus have not previously been
reported to be associated to psoriasis susceptibility we investi-
gated this further in two large psoriasis data sets. First we ana-
lysed genotyped data from the WTCCC2 psoriasis study,
excluding known PsA samples (cases n=1784, controls
n=5175), for rs2476601 and found no evidence for association
(p=0.34). Second we searched summary statistics from the
largest psoriasis study to date (cases n=10 588, controls
n=22 806) using the ImmunoBase database and again found no
evidence for association of rs2476601 to psoriasis susceptibility
(p=0.49). Using genotype data from the PsA Immunochip study
and WTCCC2 we directly compared the effect estimates for
rs2476601 in PsA and psoriasis using multinomial logistic
regression and we found the estimates to be signiﬁcantly differ-
ent (p=3.2×10−4). A direct comparison of genotypes for PsA
(n=1962) and psoriasis (n=1784) found signiﬁcant association
to an increased risk of PsA (p=4.4×10−4, OR=1.3).
Given that rs2476601 is a genetic risk factor for RA we were
concerned that the observed p value in the discovery study was
a false positive due to phenotype misclassiﬁcation caused by the
presence of unidentiﬁed RA samples in the case cohort.
However, we found the association to rs22476601 in the PsA
Immunochip data was unaffected by the inclusion of the
RA-GRS (p=1.29×10−5 vs PGRS=1.30×10
−5).
DISCUSSION
In this study we present evidence for association of rs2476601
to susceptibility of PsA exceeding the threshold recognised as
genome-wide signiﬁcant (p<5×10−8) for the ﬁrst time. In add-
ition we used genotype data and summary statistics from two
large psoriasis studies to demonstrate that this locus is differen-
tially associated to PsA and not psoriasis per se. We also conﬁrm
association of PsA with a previously reported psoriasis locus,
NOS2, bringing the total number of conﬁrmed, genome-wide
signiﬁcant, PsA loci to 10 including 4 that are PsA-speciﬁc
(HLA-B, chromosome 5q31, PsA-speciﬁc variants within IL23R
and now PTPN22). Studies have shown that PTPN22 is a
potent inhibitor of T cell activation and it is possible that the
effect may differ between T cell subpopulations.12 For example
we have shown that CD8+ T cells are important for PsA, while
this has not been reported in psoriasis.5
Strengths of the current study include the large sample sizes
used, which allowed us to conﬁrm association at accepted
genome-wide thresholds. Previous studies of this locus in PsA
have been limited by small sample size; results have either
shown weak evidence for association;13 14 weak association in
men only15 or no evidence for association at all.16 Indeed, our
previous attempts to investigate rs2476601 and PsA susceptibil-
ity failed to ﬁnd any evidence of association.17 This previous
study had approximately 60% power to detect an effect of the
size estimated in the current study. The absence of association
for rs2476601 in the Italian cohort of this study is attributed to
reduced power due to the much lower MAF (ﬁgure 2). Previous
investigations of the rs2476601 PTPN22 variant with psoriasis
have consistently reported no evidence for association,18 19 but
some have found association to other variants in the region, for
example to rs3789604 (RSBN1) or haplotypes spanning
PTPN22.20 21 However, in the largest psoriasis genetic associ-
ation study performed to date, no association was detected to
either rs2476601 or rs3789604 (p=0.49 and p=1.00, respect-
ively).8 Indeed, a direct comparison of psoriasis and PsA con-
ﬁrmed that the rs2476601 association is PsA-speciﬁc, making it
the fourth such locus to be identiﬁed.
In contrast to the previous reports, the study presented here
is performed in a large cohort of 3139 cases and 11 078 con-
trols, includes independent validation and, for the ﬁrst time,
reports conﬁrmed association with susceptibility to PsA exceed-
ing genome-wide signiﬁcance (p=1.49×10−9). The identiﬁca-
tion of PsA-speciﬁc loci is vital in terms of understanding the
different pathways involved, which may require different treat-
ments, and for future screening strategies to identify subjects at
risk of developing PsA in patients with psoriasis.
The SNP, rs2476601, has been found to be associated with
multiple autoimmune diseases including RA, where the associ-
ation is predominantly found in anti-citrullinated protein anti-
body (ACPA)-positive subjects, although association in the
ACPA-negative subgroup has been reported.22 One possibility,
therefore, is that the association with PsA could be due to the
inclusion of patients with RA and coincidental psoriasis in the
PsA cohort. Unfortunately, ACPA or rheumatoid factor status
was not available for many samples. A strength of the current
study, however, is that we used a GRS of known RA loci, which
Figure 2 Forest plot of effect
estimates for rs2476601 from the
Immunochip, validation and
meta-analysis. Rows are labelled by
study group and include MAF,
p values, ORs and 95% CIs. Reported
MAF is estimated from control group,
for Immunochip cohort this is
estimated from UK controls. CI,
conﬁdence interval; minor allele
frequency; OR, odds ratio.
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has been previously shown to adequately control for potential
phenotype misclassiﬁcation, to explore this possible confounder
and found that the association with PsA remained statistically
signiﬁcant even after this adjustment.10
In conclusion we report for the ﬁrst time genome-wide sig-
niﬁcant association of the rs2476601 variant in the PTPN22
gene with susceptibility to PsA consistent with reports in many
other autoimmune diseases. In addition, we use genotype data
from a large psoriasis study to demonstrate that rs2476601 is
differentially associated to PsA and not psoriasis.
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